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Until 1992, the conventional view of transplantation immunology was what we have 
referred to as the one-way paradigm (FIG. 1A and B), a conceptual framework that 
had been extrapolated from the neonatal tolerance model of Billingham, Brent, and 
MedawarY In Medawar's defenseless recipient experiments, and in the parent to 
offspring F j hybrid and recipient cytoablation models (FIG. 1A), it was learned in 
the 1950s that the risk of lethal graft-versus-host disease (OVHD) after splenocyte 
or bone marrow transplantation was directly proportional to the degree of MHC 
incompatibility. 
As early as 1959, it was known that all the same rules applied when whole organs 
containing immunologically active cells, such as the intestine, were transplanted. 
Thus, any kind of hematolymphopoietic transplantation was conceived to be an 
essentially one-way cellular transaction, yielding either OVHD, rejection, or tolerance. 
THE DEFECTIVE ONE-WAY PARADIGM 
In this context, it was perfectly logical to view solid organ transplantation as a 
mirror image of the bone marrow experiments, the difference being that the graft 
was the defenseless victim instead of being the aggressor (FIG. 1B). This one-way 
paradigm in the opposite direction became the disorienting dogma upon which most 
clinically directed transplantation research was based for the next third of a century. 
The One-Way In Vitro Tests 
Ironically, the introduction of in vitro models beginning with the one-way mixed 
lymphocyte reaction (MLR) in 19633.4 further supported this dogma. These so-called 
aThis work was aided by Project Grant No. DK 29961 from the National Institutes of Health, 
Bethesda, Maryland. 
b Address for correspondence: Thomas E. Starzl, MD. PhD. Department of Surgery. 3601 Fifth 
Avenue. 5C Falk Clinic. University of Pittsburgh, Pittsburgh, Pennsylvania 15213. 
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"minitransplant models" generated thousands of increasingly sophisticated cellular 
and ultimately molecular studies of immunologic interactions, the full understanding 
and clinical exploitation of which was hampered by the restrictive context of the 
one-way paradigm. 
With Clinical Bone Marrow Transplantation 
Aside from the overwhelming support provided by the unidirectional in vitro 
tests, the one-way paradigm was ostensibly strengthened in 1968 when the strategy 
of recipient cytoablation before bone marrow transplantation finally was extended 
from the mouse model to successful clinical application, emphasizing at every step 
the need for HLA compatibility if stable engraftment (called tolerance) was to be 
accomplished without the complication of GVHD.5•b 
With Whole Organ Transplantation 
However, the one-way paradigm never explained what was being observed and 
accomplished with organ transplantation without dependence on MHC matching, 
without host preconditioning, and with no GVHD. Because of these striking "viola-
tions of rules," organ transplantation was dissociated from the kind of rational 
scientific base enjoyed by those involved in bone marrow transplantation. In fact, 
the tumultuous development of the whole organ field can only be described as 
empirical. Treatment was based on the assumption that continuous immunosuppres-
sion would be required for life to maintain adequate graft function. 
The avalanche of clinical whole organ cases began in 1962-1963 when kidney 
recipients were treated with the combination of azathioprine and prednisone at the 
University of Colorado.7 A characteristic postoperative pattern was recognized in 
which rejection was found surprisingly to be easily reversed with augmented doses 
of prednisone. More importantly, maintenance immunosuppression could later be 
progressively reduced and even stopped in some cases. The same sequence of immuno-
logic crisis and resolution has since been seen with all other organs successfully 
transplanted and with all of the clinical immunosuppressive regimens (FIG. 2). Some-
thing appeared to have changed in the host, the graft, or both. But what? 
THE DISCOVERY OF CHIMERISM 
A plausible answer was found in 1992, when a group of the original still surviving 
Colorado kidney recipients (then approaching 31 years posttransplantation) and more 
than 2 dozen liver recipients (10- 23 years posttransplantation) were restudied. 8-1J A 
low level of donor leukocyte chimerism was ubiquitously found in biopsies obtained 
of the graft, of multiple host tissue sites, and in blood. 
The chimerism was thought to be multilineage, but the dominant cell population 
had the morphologic characteristics of dendritic cells. Because the number of donor 
cells was small. skeptics claimed, and perhaps some still do, that these cells were 
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FIGURE 2. Postoperative events using the one-way paradigm to interpret events after success-
ful whole organ transplantation. 
merely an epiphenomenon of tolerance (or graft acceptance), not the cause of it. 
However, this position has become increasingly difficult to justify. 
Confirmatory evidence of donor HLA alleles was obtained with polymerase chain 
reaction (PCR). Karyotyping in patients with opposite-sex donors, with either in situ 
hybridization or PCR, yielded similar results. All 30 of the chronically surviving 
kidney and liver recipients studied in 1992 were chimeras. The leukocytes of bone 
marrow origin, which are resident in all tissues, apparently had migrated and been 
assimilated by the overwhelmingly larger immunologic network of the host. In es-
sence, a small fragment of disseminated extramedullary donor bone marrow, depicted 
in FIGURE I C as a bone silhouette, had accidentally been engrafted. These observations 
provided the basis for the formulation of the two-way paradigm. 
THE TWO-WAY PARADIGM 
In the two-way paradigm, the immunologic confrontation following whole organ 
transplantation involved a graft-versus-host (GVH) as well as host-versus-graft (HVG) 
component in which the two cell populations were somehow reciprocally modulating, 
provided that both could survive (FIG. 3). Veto cells, suppressor cells, cytokine profile 
changes, and the development of enhancing antibodies seemingly had an accessory 
and ultimately crucial role in the development of reciprocal nonreactivity (FIG. 1 C). 
However, these were derivative from the primary event of the David versus Goliath 
mutual cell engagement. The umbrella of immunosuppression that equally covered 
both in the empirically developed clinical protocols had permitted these changes. 
It could be seen that the vast gap between the fields of bone marrow and whole 
organ transplantation merely reflected entrenched differences of treatment strategy, 
leaving intact the mutually censoring immunologic limbs with organ transplantation 
and deliberately trying to remove one of the limbs for bone marrow grafting proce-
dures, following a recipient cytoablation. 
However, one detail remained before the linkage was seamless. Although complete 
donor chimerism had long been assumed to be the objective of bone marrow trans-
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FIGURE 3. Postoperative events in the two-way paradigm after whole organ transplantation. 
The small lower curve is the graft-versus-host reaction which usually is silent. 
plantation, Thomas and others l4,15 recently showed that in recipients of bone marrow 
from opposite sex donors, a trace population of recipient leukocytes can always be 
detected with sensitive molecular techniques. Thus, the veto and other accessory 
events at the cellular interface are the same in principle with bone marrow as with 
organ transplantation (FIG. ID). 
With either approach to treatment (that for whole organs versus that for bone 
marrow), the resulting reciprocal nonreactivity of the two populations is a natural 
event that apparently is only permitted, not caused, by the drugs we use. Chaperoned 
would be a better term, because it does not seem to matter where these agents interdict 
the allogeneic response: from the second signal transduction proximally (i.e., with 
CTLA4Ig fusion proteins) to the most distal inhibition of p70 S6 kinase activity by 
rapamycin or any site in between. By choosing an "easy" strain combination of 
rodents, these agents as well as dozens of less potent molecules sometimes have 
been made to look like Hercules, when a single dose or multiple doses were shown 
to induce permanent donor-specific tolerance, when in fact the model (not the drug) 
was the principal factor. 
EXPERIMENTAL CLARIFICATION 
A Rat Model 
In an illustrative experiment of tolerance induction across a moderately difficult 
barrier,16 Brown Norway rat recipients were transplanted with four different fully 
allogeneic Lewis organs (liver, heart, kidney, and intestine) or with a standard dose 
of Lewis cell suspensions from four different sources (bone marrow, thymus, spleen, 
and lymph node), with or without immunosuppression with tacrolimus. 
No Treatment. As expected without immunosuppression, all Lewis cell suspen-
sions were rejected by the Brown Norway recipients. There was no mortality, but 
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after 100 days, there was no chimerism. The hearts, kidneys, and intestines were 
rejected after 7.5-12 days and the livers in 28 days. 
Transient Tacrolimus (FK 506) Treatment. A 2-week course of treatment with 
tacrolimus with two supplementary single doses at days 20 and 27 dramatically 
changed the outcome.16 All hearts, kidneys, and livers now survived to 100 days, 
drug free for the last three quarters of this time. Bone marrow engrafted silently with 
no overt evidence of GVHD. The intestines were not rejected. However, all of the 
bowel recipients died of GVHD at about 45 days. Spleen and lymph node cell 
suspensions behaved like intestine, always causing GVHD. Thymocytes failed to 
engraft. 
The striking divergence of outcome with different allografts reflected their cellular 
composition. 16 The lack of some essential factor(s) may account for the failure of 
engraftment of T-cell-rich adult thymocytes. The infusion of T- and B-cell-rich 
splenocytes and lymph node cells led to GVHD, whereas engraftment of the clinically 
inocuous bone marrow correlated with a large component of immature cells of 
undetermined phenotype. 
At 100 days, the animals successfully engrafted with bone marrow, heart, or liver 
underwent examination with in vitro mixed lymphocyte reaction and cytotoxic assays. 
These revealed consistent anti-donor reactivity (so-called split tolerance). Now drug 
free, the animals accepted challenge livers from donor, but not third-party animals. 
The hepatic allografts went through spontaneously resolving rejection in rats primed 
originally with either donor-strain hearts or bone marrow. After passing through these 
crises, all of the orthotopically transplanted challenge livers permanently supported 
life and thereafter were completely normal histopathologically. 
Challenge heart grafts that normally are rejected in 8 days were also accepted 
by the drug-free animals primed with liver, bone marrow, or heart, with no clinical 
failures in any of these groups. However, when examined histologically, the challenge 
hearts appeared completely normal at 100 days posttransplantation only in rats primed 
originally with donor-strain liver. In rats that had been primed with bone marrow, 
challenge hearts had the subendothelial infiltration of recipient lymphoid cells (called 
Quilty lesions) that are generally considered as very early premonitors of chronic 
rejection. 16 
Animals primed originally with hearts were at the lowest end of the tolerance 
scale. Challenge hearts in these rats also escaped clinical rejection and continued to 
function along with the priming hearts, but at the 200-day milestone both first and 
second hearts showed the classic proliferative arterial lesions of chronic rejection as 
well as low grade cellular infiltration. 
The Tolerance/Chimerism Relation. The spectrum of tolerogenicity defined by 
histopathologic outcome was liver best -> bone marrow next -> heart least. These 
results correlated with the chimerism produced by the priming transplant. The lineage 
composition of the chimerism caused by the tolerogenic priming allografts included 
T and B lymphocytes and was qualitatively similar to that caused by the transplantation 
of GVHD-inducing allografts such as intestine, lymph node cells, or splenocytes. 
However, there were fewer total number of donor leukocytes in the recipient tissues, 
a smaller proportion of T cells, and a more prominent population of cells of myeloid 
lineage, notably dendritic cells. 16 
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Mouse Liver Transplantation 
The use of drugs like tacrolimus in such models could obscure the search for 
fundamental mechanisms of natural tolerance. Consequently, the spontaneous toler-
ance induced by orthotopic liver transplantation in the mouse model has presented 
unique opportunities for investigation, particularly because so much about mammalian 
immunology is learned from this species. Qian et al. 17 have shown that in virtually 
all strain combinations. the majority of mouse liver recipients survive permanently 
without immunosuppression. 
As in the rats, low levels of donor cell chimerism were typically observed in 
animals followed for more than 300 days posttransplantation. As expected, the liver 
recipients accepted subsequently transplanted donor heart and skin despite retention 
of donor specific MLR and CML reactivity (again split tolerance). It was noteworthy 
that the induction of donor-specific nonreactivity by primary heterotopic heart trans-
plants in some strain combinations precluded completion of these experiments. This 
induced tolerance by the mouse heart as well as the observations made in rats showed 
that such tolerogenicity that is most readily induced with hepatic grafts is not organ-
specific. Hepatic tolerogenicity is only an extreme illustration of a cardinal principle 
operational with all tissues and organs, based on donor leukocyte migration and 
chimerism. 17 
The Nature of Cell Migration 
This trafficking of donor leukocytes after whole organ transplantation was de-
scribed in the classic 1981 article by Nemlander and coworkers 18 of Helsinki. This 
was in the context of allosensitization as emphasized a decade later in the equally 
classic studies of dendritic leukocyte migration after heterotopic cardiac transplanta-
tion in mice by Larsen et al. 19 However, our investigations placed the phenomenon 
of donor cell migration squarely in the context of tolerance, both in transiently 
immunosuppressed rats l6.20 and in drug-free mice.17 With both species, the migratory 
donor cells began to home to the central and secondary lymphoid organs within 
minutes after transplantation. After pausing there for 1 or 2 weeks,!7,2O they broke 
out and became generalized, including the skin where they can so easily be found 
in patients. 
THE DONORIRECIPIENT CELLULAR INTERFACE 
The question of how the chimeric cells survive and induce donor-specific tolerance 
was examined by a team that included Angus Thomson, Anthony J. Demetris, and 
the husband and wife team of Drs. Lina Lu and Shiguang Qian. The hepatic leukocytes 
were the target of their investigation because of overwhelming evidence that the liver 
was more tolerogenic than any other organ. After discarding the hepatocytes and 
duct cells. approximately 107 nonparenchymal cells (NPCs) could be obtained from 
one mouse liverY 
The technology with which the suspect tolerogenic cells were studied was de-
scribed in 1992 by Inaba and co-workers.22.23 Following in their tracks, Thomson and 
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FIGURE 4. Experimental design in mice in which peripheralized donor leukocytes in whole 
organ allografts were shown to migrate and form self-perpetuating peripheral cellular oases. 
(See text for discussion.) 
Lu cultured the NPCs in GM-CSF enriched medium. After 4 or 5 days of culture, 
approximately 2 x 106 cells with dendritic morphology and surface phenotype were 
identified. 21 A subpopulation of these cells formed clusters on the bottom of the 
culture wells. Loosely adherent cells were harvested and further cultured and studied 
according to the methods described by Inaba and co-workers.",2) Although they had 
the phenotype and function of precursor dendritic cells, it was difficult at fust to 
prove their dendritic leukocyte origin because it was impossible to drive them to 
maturation, even with the addition of gamma-interferon and tumor necrosis factor. 
They had poor allostimulatory function, expressed low levels of MHC class II antigen, 
and were avidly phagocytic.'! 
This impasse was broken when the culture wells were coated with Type I collagen, 
thus stimulating the natural microenvironment of liver where mature dendritic cells 
are normally known to reside. Under these conditions, the precursor cells in the wells 
promptly assumed the properties of mature dendritic cells, now expressed high levels 
of MHC class II antigen, and acquired potent allostimulatory activity. The question 
of whether these unusual cells would mature and express class II antigen in vivo was 
investigated by injecting the purified precursor cells from B 1O.BR livers into the 
footpad of fully allogeneic B 10 mouse recipients. The cells migrated promptly to 
the T-cell areas of the central lymphoid organs where they were easily phenotyped 
as donor and shown to express high levels of class II antigen. 21 
In the crucial next step, liver transplantation was carned out in the fully allogeneic 
but nonrejecting mouse stain combination (B 10 to C3H).24.25 The recipient animals 
were of course chimeric, and samples were collected from their bone marrow, spleen, 
thymus, and lymph nodes (FIG. 4). Donor as well as recipient precursor dendritic 
cells, at variable stages of maturation, were demonstrated in these samples, using 
the same culture techniques as had been used previously for study of liver-derived 
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NPCs. These observations suggest that these cells are derived from precursor dendritic 
cells and presumably pluripotent stem cells that have migrated from the graft and 
have widely distributed throughout the recipient tissues.24.25 The profile and the ease 
with which these peripheralized cells (both donor and recipient) could be identified 
were much the same 4, 14. or 150 days after liver transplantation. 
Although the same events occurred in heart recipients who rejected their allografts, 
the peripheralized donor cells were transient and could no longer be found 30 days 
after cardiac transplantation. 25 Although the cellular beachhead was the same, it was 
too feeble to be self-sustaining. 
Thus, it appears that after transplantation, allografts export immature dendritic 
and probably stem cells, which establish residence in many preactive niduses within 
the recipient tissue, creating widespread and persistent cellular oases, presumably 
swimming in cytokines and other growth factors. Lu et al. 25 have obtained evidence 
that the dendritic precursor cells may be tolerogenic. These remarkable findings have 
suggested not only a mechanism for perpetuation of the migratory dendritic cells. 
but also a means by which the chimeric cells can exert a tolerogenic effect. 
CLINICAL DONOR LEUKOCYTE AUGMENTATION 
If our hypothesis of the mechanism of graft acceptance is correct, it should be 
possible to safely facilitate this process by adding unaltered donor bone marrow 
perioperatively to the minimal dose of the so-called passenger leukocytes contained 
in a whole organ allograft. Such a trial is well underway in Pittsburgh26-28 and now 
includes 89 patients entered between December 1992 and February 1995. Donor 
bone marrow cells, obtained from cadaveric vertebral bodies, were not T-cell depleted 
or modified prior to infusion. Subsequent to organ placement, 3-5 x 108 cellslkg 
were infused into nonconditioned recipients who were then maintained on routine 
immunosuppression with tacrolimus and prednisone. No complication of bone marrow 
infusion was observed in any of the 89 primary whole organ transplant recipients, 
and their convalescence was rapid. The cumulative risk of rejection was similar in both 
bone marrow augmented and nonaugmented recipients and there was no incidence of 
serious GVHD. The results of this study are summarized in TABLE 1. 
CONCLUSION 
In FIGURE I, the bottom panels (C, D) portray what transplantation immunology 
looks like after eliminating the blindfold of the one-way paradigm, which is depicted 
in the upper panels. A third of a century ago, Simonsen29 and Michie, Woodruff, 
and Zeiss)O challenged the one-way paradigm. While sound, their views were not 
accepted because the ideas could not be proved. In experiments prior to this, Martinez, 
Shapiro, and Good'l described, without recipient cytoablation or immunosuppression, 
mutual immunologic tolerance in parabiotic mice, that could only be explained by 
the two-way paradigm. In retrospect, the resemblance its obvious of Good's mutually 
tolerogenic parabiotic partners. the allograftlhost cellular relationship of our experi-
ments, and for that matter the observations of chimerism in Freemartin cattle by 
Owen in 1945.)2 
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TABLE 1. Function and Actuarial One-Year Graft Survival of Bone Marrow 
Augmented and Nonaugmented Whole Organ Transplant Recipients 
Function ex ± SD) 
Cardiac 
Graft Bilirubin Creatinine Output 
Organs Transplanted n Survivala (mg/dl) (mg/dO (L/min) FEV! (L) 
Bone Marrow Augmented 
Liver 34b 31 (91%) 0.8 ± 0.6 
Kidney 40' 39 (98%) 1.7 ± 0.6 
Heart 10 08 (80%) 6.0 ± 1.7 
Lungs 05 05 (100%) 2.0 ± 2.0 
Controls 
Liver 33 26 (79%) 0.7 ± 0.3 
Kidney 21d 18 (86%) 2.2 ± 1.5 
Heart 04 06 (100%) 6.3 ± 3.2 
Lung 01 0 
a Actuarial I-year graft survival. 
b One type I diabetic also received pancreatic islets; not insulin-free. 
, Nineteen type I diabetics also received either whole organ pancreas (n = 13) or isolated 
pancreatic islets (n = b); II patients (all recipients of pancreases) are insulin-free. 
d Four type I diabetics also received whole organ pancreas transplants; two are currently off 
insulin, 
The continuity of this theme was interrupted in the early 1960& and not restored 
until 1992, when our observation regarding the persistence of donor cells in long-
term allograft recipients exposed the cellular events that transpire after organ trans-
plantation. The therapeutic implications of the two-way paradigm, including the 
iatrogenic augmentation of spontaneous chimerism with periopl!rative unaltered donor 
bone marrow, are obvious. In our clinical trials, adjuvant bone marrow under conven-
tional tacrolimus/prednisone immunosuppression has never caused clinically signifi-
cant GVHD, Levels of chimerism 1,000 times greater than that occurring spontane-
ously have been regularly produced. 
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